Short answer
ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Exclusive Greater China license for ARR-002 granted to Shanghai Allist, with sublicensing rights and royalty-bearing economics.
ArriVent BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive Greater China license for ARR-002 granted to Shanghai Allist, with sublicensing rights and royalty-bearing economics
- ArriVent retains ARR-002 rights outside Greater China and the right to manufacture within the territory
- Potential consideration up to $80.6 million, including upfront and development, regulatory, and sales milestones
- Tiered royalties ranging from mid-single-digit to low-double-digit percentages on licensed-product sales
- Allist leads Greater China development and commercialization while ArriVent supplies the initial joint global clinical study
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 furnished under Item 2.02, but not incorporated into other SEC filings
- Disclosure receives limited liability protection under Sections 11, 12(a)(2), and 18
Item EX-99.1 · Exhibit EX-99.1
- $373.1M cash and investments expected to fund operations into 2028, reducing near-term financing risk
- Firmonertinib pivotal Phase 3 topline data expected in 2H 2026, the key near-term value catalyst
- Six-month net loss $93.2M versus $95.8M, while R&D declined to $80.0M from $89.0M
- ARR-217 entered Phase 1b dose optimization and ARR-002 first-patient dosing expected Q3 2026, broadening pipeline catalysts
- Six-month G&A increased to $18.8M from $11.4M, contributing to continued operating losses
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ArriVent BioPharma, Inc. 8-K filings
Get the next AVBP 8-K as it lands
Follow AVBP for push alerts, or ask the research agent what this filing means.